NOT-GM-23-032: Notice of NIGMS Withdrawal of Participation from PA-22-177 "PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)"

Notice of NIGMS Withdrawal of Participation from PA-22-177 "PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)"

Notice Number:

NOT-GM-23-032

Key Dates

Release Date:

February 23, 2023

Related Announcements

PA-22-177 - PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

Issued by

National Institute of General Medical Sciences (NIGMS)

Purpose

The purpose of this Notice is to inform the community that the National Institute of General Medical Sciences (NIGMS) is discontinuing participation in PA-22-177 “PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trials Required)” effective immediately. NIGMS will not accept New, Resubmission, Renewal, or Revision applications for PA-22-177 for the April 5, 2023 application due date and beyond.

NIGMS will continue to accept applications to the PA-22-176 “PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)”.

Inquiries

Please direct all inquiries to:

Eddie Billingslea, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Email: [email protected]